Company Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa.
It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine.
It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products.
It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD).
The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Ofer Haviv |
Contact Details
Address: 13 Gad Feinstein Street, Park Rehovot Rehovot, 7638517 Israel | |
| Phone | 972 8 931 1900 |
| Website | evogene.com |
Stock Details
| Ticker Symbol | EVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574565 |
| CUSIP Number | M4119S104 |
| ISIN Number | IL0011050551 |
| SIC Code | 2870 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dan Jacob Gelvan Ph.D. | Chief Executive Officer of Ag Plenus Ltd. |
| Yoash Zohar | Chief Executive Officer of Casterra Ag Ltd. |
| Ofer Haviv CPA | Chief Executive Officer, President and Director |
| Polina Ravzin | Chief Financial Officer |
| Dr. Ilia Zhidkov | Chief Technology Officer |
| Liat Foigel Wejgman | Vice President of Human Resources |
| Dr. Gabi Tarcic Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2026 | EFFECT | Notice of Effectiveness |
| Apr 3, 2026 | EFFECT | Notice of Effectiveness |
| Apr 2, 2026 | 6-K | Report of foreign issuer |
| Mar 26, 2026 | F-3 | Filing |
| Mar 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 26, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Feb 25, 2026 | 6-K | Report of foreign issuer |
| Feb 19, 2026 | D | Notice of Exempt Offering of Securities |